{
    "2019-04-01": [
        [
            {
                "time": "2023-04-15",
                "original_text": "Big Pharma Stocks to Add to Your Portfolio This April",
                "features": {
                    "keywords": [
                        "Big Pharma",
                        "Portfolio",
                        "April"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2023-04-16",
                "original_text": "BMOâ€™s Got A Point About Teva Stock, But Are Investors Willing To Listen?",
                "features": {
                    "keywords": [
                        "BMO",
                        "Teva",
                        "Stock",
                        "Investors"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2023-04-17",
                "original_text": "Arteaus Therapeutics Sells Emgality Royalty to Royalty Pharma for $260 Million",
                "features": {
                    "keywords": [
                        "Arteaus",
                        "Therapeutics",
                        "Emgality",
                        "Royalty",
                        "Pharma",
                        "$260 Million"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}